IT-миллионер из РФ подарит миллион долларов за 123 года жизни

По его словам, человеческое общество обладает одной интересной чертой – соревновательностью и стремлением к рекордам. Этой характеристикой Каминский планирует воспользоваться для того, чтобы превратить долголетие в своеобразную спортивную дисциплину, в которой будут соревноваться все жители Земли.

Российский бизнесмен Дмитрий Каминский пообещал наградить первого человека, достигшего возраста в 123 года, миллионом долларов CША и вместе с ним отпраздновать день рождения ради зарождения "гонки долголетия" среди стариков и повышения внимания общества к проблемам продления жизни, сообщает пресс-служба венчурного фонда Deep Knowledge Ventures.

"Многие пожилые люди говорят сегодня, что они устали жить. Это эволюционный и социальный феномен, который я хочу изменить. В последние годы мир все больше входит в гонку долгожительства. Я ставлю мое собственное здоровье и деньги ради достижения этой цели, однако все наши усилия будут напрасны, если нам не удастся убедить стариков стремиться к жизни", — заявил Каминский.

По его словам, человеческое общество обладает одной интересной чертой – соревновательностью и стремлением к рекордам. Этой характеристикой Каминский планирует воспользоваться для того, чтобы превратить долголетие в своеобразную спортивную дисциплину, в которой будут соревноваться все жители Земли.
Текущая цель Каминского – увидеть человека, которому удастся побить рекорд Жанны Кальман, дожившей до 122 лет и 6 месяцев.

По словам бизнесмена, его фонд будет активно способствовать реализации этой цели, способствуя развитию технологий, которые помогут человечеству продлевать жизнь. В ближайшие годы, по оценкам аналитиков компании, в этой сфере начнется настоящая "гонка вооружений".

"Индустрия долгожительства в скором времени переживет бум инвестиций, который будет больше, чем тот подъем, который был вызван "доткомами" Интернета в конце 90 годов, так как бизнес в глобальной сети ограничен относительно небольшой аудиторией. Долгая и здоровая жизнь, с другой стороны, в интересах каждого жителя планеты", — добавил Каминский.

Who can get 1 million dollar after 123 years old?

In the last few years, major anti-aging companies, such as Google's Calico and J. Craig Venture's new San Diego-based genome sequencing start-up Human Longevity Inc, have launched.

Along side this, Billionaires like Larry Ellison, Sergey Brin, Peter Thiel, Paul F. Glenn, and Dmitry Itskov are also funding research into longevity science.

Itskov is the founder of the 2045 Initiative with the goal of helping humans achieve physical immortality within the next three decades.

Reuters reported that gerontologist Dr Aubrey de Grey, chief scientist at SENS Research Foundation and Anti-Aging Advisor to the US Transhumanist Party, thinks scientists may be able to control aging in the near future. 'I'd say we have a 50/50 chance of bringing aging under what I'd call a decisive level of medical control within the next 25 years or so,' he said. 

A Russian multi-millionaire whose dream it is to live forever has promised to give $1 million to the first person to reach the age of 123.

Dmitry Kaminskiy, a senior partner of Hong Kong-based firm, Deep Knowledge Ventures, is hoping his million dollar gift will trigger a new group of 'supercenternarians'.

He says research into stem cells, tissue rejuvenation and regenerative medicine will allow people to live beyond 120 - an age that has been quoted as the 'real absolute limit to human lifespan'. 'We live in the most exciting era of human development when technologies become exponential and transformative,' Kaminskiy told DailyMail.com. 

Kaminskiy is hopeful people will soon start living to 150 years of age with longevity science improving. Studies in stopping and reversing aging in mice have already shown some success, and people around the world are generally living longer all the time.

For example, life expectancy hit an all time high of nearly 79 years-old in 2014 in America according to a report from Centers for Disease Control and Prevention's National Center for Health Statistics. 

Additionally, Britain's oldest person, Ethel Lang, just died at the age of 114. She was believed to be the last person living in the UK who was born in the reign of Queen Victoria. Whether Kaminskiy's million dollar prize will encourage people to live 

longer is still to be seen.

 

Пари

Два влиятельных бизнесмена, занимающиеся разработкой новых методик против борьбы со старением заключили пари: тот из них, кто проживет дольше получит от проигравшего один миллион долларов. О столь необычно споре, информирует Gizmodo Australia.

Во время крупнейшей американской инвестиционной ярмарки в сфере здравоохранения - JPMorgan Health Care Conference бизнесмены-геронтологи заключили пари, чтобы доказать свою уверенность в том, что науке под силу остановить процесс старения человеческого организма.

Участниками спора стали - глава специализирующейся на изобретении медпрепаратов против старения биотехнологической компании Insilico Medicine Inc. Алекс Жаворонков и его компаньон по команде по борьбе с раком Дмитрий Каминский, который также является старшим партнером гонконгского венчурного фонда Deep Knowledge Ventures.

По условия их спора один миллион долларов в акциях Insilico Medicine от лица умершего первым бизнесмена перейдет ко второму участнику спора. Договор утратит силу в том случае, если оба участника спора доживут до ста лет. Также было оговорено условие, согласно которому Жаворонков и Каминский пообещали не способствовать смерти друг друга, то есть, не будут нанимать убийц, подстраивать несчастные случаи, травить друг друга и все прочее.

Напомним, Дмитрий Каминский и Алекс Жаворонков вместе с биологом Антоном Буздиным и биофизиком-математиком Николаем Борисовым занимались разработкой системы «Онкофайндер», которая позволяет подбирать препарат для лечения конкретной опухоли, а также может использоваться для поиска новых лекарств при лечении рака. Эта система не имеет аналогов в мире и сейчас проходит тестирование в нескольких российских онкологических клиниках.

About InSilico Medicine

InSilico Medicine was founded in early 2014 and has since developed GeroScope platform for geroprotectors discovery and utilized the OncoFinder platform under exclusive license from Pathway Pharmaceuticals (Hong Kong) for drug discovery and drug repurposing in oncology.. It is a company dedicated to finding novel solutions towards aging and age-related diseases using advances in genomics and big data analysis. Through internal expertise and extensive collaborations with brilliant scientists, institutions, and highly credible pharmaceutical companies, InSilico Medicine seeks to revolutionize personalized science and drug discovery. More can be read about InSilico Medicine, Inc. at http://www.insilicomedicine.com.

NewScientist : Everyday drugs could give extra years of life

Drugs to slow ageing sound futuristic but they already exist in the form of relatively cheap medicines that have been used for other purposes for decades. Now that their promise is emerging, some scientists have started using them off-label in the hope of extending lifespan – and healthspan. "We are already treating ageing," said gerontologist Brian Kennedy at the International Symposium on Geroprotectors in Basel, Switzerland, last week, where the latest results were presented. "We have been doing ageing research all along but we didn't know it."

Last year Google took its first steps into longevity research with the launch of Calico, an R&D firm that aims to use technology to understand lifespan. Geneticist Craig Venter announced he is pursuing a similar goal via genome sequencing. Now pharmaceutical companies look set to join in. At the conference, the head of Swiss drug firm Novartis said research into "geroprotectors" or longevity drugs was a priority.

Google and Venter's plans may have injected an over-hyped field with a measure of credibility but they are unlikely to bear fruit for some time. Yet evidence is emerging that some existing drugs have modest effects on lifespan, giving an extra 10 years or so of life. "We can develop effective combinations for life extension right now using available drugs," says Mikhail Blagosklonny of the Roswell Park Cancer Institute in New York.

One of the most promising groups of drugs is based on a compound called rapamycin. It was first used to suppress the immune system in organ transplant recipients, then later found to extend lifespan in yeast and worms. In 2009, mice were added to the list when the drug was found to lengthen the animals' lives by up to 14 per cent, even though they were started on the drug at 600 days old, the human equivalent of being about 60.

This led to an explosion of research into whether other structurally similar compounds – called rapalogs – might be more potent. Now the first evidence has emerged of one such drug having an apparent anti-ageing effect in humans. A drug called everolimus, used to treat certain cancers, partially reversed the immune deterioration that normally occurs with age in a pilot trial in people over 65 years old.

Immune system ageing is a major cause of disease and death. It is why older people are more susceptible to infections, and why they normally have a weaker response to vaccines.

That weak response, however, has proved useful for studying ageing, as it provides an easy read-out of immune system health. "In humans you can't do decades-long clinical trials," says Novartis researcher Joan Mannick. Instead, the company looked at a proxy that would quickly show results.

They gave 218 people a six-week course of everolimus, followed by a regular flu vaccine after a two-week gap. Compared with those given a placebo, everolimus improved participants' immune response – as measured by the levels of antibodies in their blood – by more than 20 per cent, to two out of the three vaccine strains tested.

Of the three everolimus doses tested, the highest caused fatigue and mouth ulcers, while two lower doses had no apparent ill effects. Previous experiments in mice with rapamycin suggest this class of drug acts by inhibiting a protein called mTOR. mTOR also seems to be affected by calorie restriction – the strategy of trying to live longer by eating less.

mTOR is involved in sensing the level of nutrients available within cells, so one idea is that when times are scarce, cells shift into energy-conserving mode, which has knock-on anti-ageing effects, including on the immune system.

Mannick stresses that the study needs repeating, and the big question, of whether the drug keeps the participants healthier, can only be settled by long-term follow-up. There's also the issue of side effects beyond those seen in the trial. High doses of rapamycin used in organ transplants seem to nudge the recipient's metabolism into a prediabetic state – a harm that might outweigh its anti-ageing effect.

For now, it is an encouraging sign that rapalogs have similar effects in people as in mice, at least on the immune system, says Alex Zhavoronkov, CEO of biotech firm InSilico Medicine in Baltimore, Maryland.

Gadd 45 expression correlates with age dependent neurodegeneration in Drosophila melanogaster

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Authors:

• Natalia Bgatova ⁽¹⁾
• Tatiana Dubatolova ⁽²⁾
• Leonid Omelyanchuk ⁽²⁾
• Ekaterina Plyusnina ^{(3) (4)}
• Mikhail Shaposhnikov ^{(3) (4)}
• Alexey Moskalev ^{(3) (4) (5)} 

Author Affiliations

 

• 1. Research Institute of Clinical and Experimental Lymphology Siberian Branch of RAMS, Novosibirsk, Russia
• 2. Institute of Molecular and Cellular Biology, Siberian Branch of RAS, 8/2, Ac. Lavrentieva Ave, 630090, Novosibirsk, Russia
• 3. Institute of Biology of Komi Science Center of Ural Branch of RAS, Syktyvkar, Russia
• 4. Syktyvkar State University, Syktyvkar, Russia
• 5. Moscow Institute of Physics and Technology (State University), Dolgoprudny, Russia

Three distinguished experts have joined InSilico Medicine

InSilico Medicine proudly announces that Donald Small, MD, PhD, Kristen Fortney, PhD and Alexey Moskalev, DSc will aid the company’s mission to successful drug discovery and personalized medicine. It is clear meaningful progress is being made to battle aging from InSilico Medicine, considering the past major SAB additions.

Alex Zhavoronkov, CEO of InSilico Medicine, puts this exciting SAB addition into context,
"Aging lies at the core of the many global problems and there is an urgent need to extend the healthy productive longevity of the aging population while staying within the regulatory and ethical frameworks and boundaries and implement novel business models that will boost the confidence of the many industry stakeholders. The addition of these three world-class experts to our SAB strengthens our ability to develop new approaches to screening for drugs that may help delay the aging processes or repair the age-associated damage. Our approach to applied aging research stems from many years of cancer research and personalized medicine and some of the tissue profiling and drug selection methods are already employed in clinical research."

Dr. Small serves as the Director of the Pediatric Oncology Division of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital. His motivation to play a role in the lives of young cancer patients tremendously impacts his research goals and long term efforts. The InSilico team is very excited to see how his experience will inspire the ongoing research and development.

“InSilico Medicine is poised to make major contributions to treat aging and other diseases. Their proprietary software and brilliant young scientists have impressed me. I look forward to contributing in any way I can to their strategies and discoveries," said Dr. Small.

Kristen Fortney is a Postdoctoral Fellow at Stanford University, where she works on the genetics of human longevity. She obtained a PhD from the University of Toronto. Her work consists of the application of computational biology tools to problems in translational medicine, focusing on aging and age-related disease. The technical guidance she will have to offer will play a large role in development and future goals of InSilico Medicine.

“InSilico Medicine has an innovative informatics approach to find new therapies that may treat age-related disease and slow aging. I am excited to join the InSilico Medicine advisory team and look forward to working with them to advance their technology," said Dr. Fortney.

Dr. Moskalev, from the Institute of Biology of Komi Science Center of RAS is Head of the Laboratory of Molecular Radiobiology and Gerontology. He also teaches at Syktyvkar State University. Much of his focus has been on DNA repair and molecular mechanisms involved with aging. Dr. Moskalev’s leadership and global knowledge of aging research will play a key role in the delivery of InSilico Medicine’s solutions.
“While experiments in model organisms are extremely important for both cancer and aging research, advances in computing, availability of the vast amount of omics data and rapidly improving understanding of the underlying molecular processes allow for the many experiments to be performed in silico. The GeroScope system developed by Insilico Medicine at the very least allows to narrow down the large lists of geroprotective drugs to be tested in animals and for some drugs and combinations directly in humans. The system may be used for improving clinical trials decisions and possibly for personalized preventative medicine," said Dr. Moskalev.

About InSilico Medicine

InSilico Medicine was founded in early 2014 and has since developed the OncoFinder and Geroscope. It is a company dedicated to finding novel solutions towards aging and age-related diseases using advances in genomics and big data analysis. Through internal expertise and extensive collaborations with brilliant scientists, institutions, and highly credible pharmaceutical companies, InSilico Medicine seeks to revolutionize personalized science and drug discovery. More can be read about InSilico Medicine, Inc. at http://www.insilicomedicine.com.
On top of this, InSilico Medicine recently announced to the public about OncoFinder, its novel algorithm that will streamline the transcriptome analysis process.

Resourse  http://www.prweb.com/releases/2014/09/prweb12195460.htm